ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults

ViiV Healthcare seeks USFDA approval to expand use of Cabenuva to every two-month dosing. (Credit: Darwin Laganzon from Pixabay.)